Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06094543 · ClinicalTrials.gov registry record · NA
Improving Overactive Bladder Treatment Access and Adherence
A NA study of Urinary Incontinence and Overactive Bladder Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06094543 is a NA study of Urinary Incontinence and Overactive Bladder Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 261-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06094543, a NA study of Urinary Incontinence and Overactive Bladder Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and undertreated with significant financial and health-related consequences. OAB syndrome is characterized by urinary urgency, with and without urinary incontinence, urinary frequency, and nocturia. Evidence-based treatments are available, including behavioral therapy, pharmacotherapy, and minimally invasive procedures. Diagnosis and treatment are also associated with improvement in urinary symptoms and overall quality of life (QOL).3 However, 70-80% of treated patients will discontinue use of therapy in the first year due to one of several factors (e.g., cost, tolerability, inadequate effect). In addition, only 4.7% progress to advanced therapies suggesting undertreatment for those that need it most. Vulnerable populations are especially at risk, as therapy utilization are lowest among older, lower income, and/or minority groups. Poor access, insufficient patient education regarding disease chronicity, expected outcomes, costs, and potential side effects lead to unrealistic patient perceptions about therapy. This leads to suboptimal therapy duration, poor treatment efficacy, adherence, and undertreatment. The study aims to evaluate a tailored patient-centered tool to begin the treatment process.
Conditions Studied
Interventions
- BEHAVIORAL Patient Engagement Tool
Study Locations (1)
California
- Stanford Pelvic Health Center - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06094543
The ClinicalTrials.gov registry entry for NCT06094543 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (89% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Patient Engagement Tool is the first listed.
NCT06094543 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06094543 about?
NCT06094543 is a clinical study titled "Improving Overactive Bladder Treatment Access and Adherence". Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and undertreated with significant financial and health-related consequences. OAB syndrome is characterized by urinary urgency, wi...
What is the current status of trial NCT06094543?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-11-01. Estimated completion is 2026-12.
What conditions does trial NCT06094543 study?
This clinical trial studies the following conditions: Urinary Incontinence, Overactive Bladder Syndrome.
What interventions are being tested in trial NCT06094543?
The interventions under investigation include: Patient Engagement Tool (BEHAVIORAL).
Who is sponsoring clinical trial NCT06094543?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06094543 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
-
Training for Urinary Leakage Improvement After Pregnancy
RECRUITING · NA
-
Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence
RECRUITING · NA
-
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.